# BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

## Overview


<b>2024/04/19</b> 22:00:02				
Price 8.69 USD				
Difference	0	1.05% (0.09)		

General attributes				
ISIN	CA0717341071			
Symbol	BHC			
Exchange	NYSE			
Currency	USD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,984 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.44 USD (100)
Ask (Ask size)	8.70 USD (1,000)
Open	8.57 USD
High	8.76 USD
Low	8.545 USD
Close (prev. day)	8.60 USD
VWAP	8.662998 USD
Volume (pcs)	2,945,834
Trading volume	25,519,166.81
Number of trades	14,373
Last size	-

<b>Futures and Options</b>	
Related Futures	14
Related Options	-

PDF Downloads	
Company report: BAUSCH HEALTH	
COMPANIES INC.	



Information about previous performance does not guarantee future performance. **Source:** FactSet

### **Recent research**

on sector			
Date		Headline	Download
2024/04/03	8.   28 27   18	Global Equity Ratings	
2024/03/13	84 (2) 21 (8)	Global Equity Ratings	
2024/02/22	8.   28 27   18	Global Equity Ratings	
2024/02/14	84 (2) 21 (8)	Global Equity Ratings	
2024/01/23	8.   28 27   18	Global Equity Ratings	




# **Details**

<b>2024/04/19</b> 22:00:02				
Price				
8.69 USD				
Difference	0	1.05% (0.09)		

General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	NYSE			
Currency	USD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,984 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	8.44 USD (100)
Ask (Ask size)	8.70 USD (1,000)
Open	8.57 USD
High	8.76 USD
Low	8.545 USD
Close (prev. day)	8.60 USD
VWAP	8.662998 USD
Volume (pcs)	2,945,834
Trading volume	25,519,166.81
Number of trades	14,373
Last size	_

Performance and Risk					
	6m 1Y 3				
Perf (%)	+18.39%	+15.41%	-70.16%		
Perf (abs.)	+1.35	+1.16	-20.43		
Beta	1.95	1.31	1.81		
Volatility	40.43	54.27	68.51		



Information about previous performance does not guarantee future performance.  $\textbf{Source:} \ \ \textbf{FactSet}$ 

Price data	
Ø price 5 days   Ø volume 5 days (pcs.)	8.66 USD (2,603,059)
Ø price 30 days   Ø volume 30 days (pcs.)	9.44 USD (3,155,643)
Ø price 100 days   Ø volume 100 days (pcs.)	8.50 USD (2,547,893)
Ø price 250 days   Ø volume 250 days (pcs.)	8.11 USD (2,915,833)
YTD High   date	11.46 USD (2024/04/03)
YTD Low   date	7.56 USD (2024/01/03)
52 Weeks High   date	11.46 USD (2024/04/03)
52 Weeks Low   date	5.57 USD (2023/05/12)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/04/ 19	22:26	8.161 EUR	0.01	2
Toronto Stock Exchange	2024/04/ 19	22:00	11.94 CAD	3.04	1,873
Stuttgart	2024/04/ 19	21:51	8.06 EUR	0.00	15
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/04/	22:00	8.69 USD	25.52	14,373



	19				
Munich	2024/04/ 19	08:03	8.107 EUR	0.00	2
Frankfurt	2024/04/ 19	15:32	8.008 EUR	0.00	3
Duesseldorf	2024/04/ 19	08:10	7.951 EUR	0.00	3
Berlin	2024/04/ 19	08:03	7.948 EUR	0.00	2



## Company profile

**Company Logo** 

### **BAUSCH** Health

#### **Contact Details**

BAUSCH HEALTH COS. INC.

\_ \_

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

### **PDF Downloads**

Company report: BAUSCH HEALTH COMPANIES INC.

đ.

### **Company Profile**

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board				
Thomas Appio	Chairman of Managing Board			
Tage Ramakrishna	Member of Executive Committee			
Cees Heiman	Member of Executive Committee			
Fernando Zarate	Member of Executive Committee			
Graham Jackson	Member of Executive Committee			
Jeff Hartness	Member of Executive Committee			
Kathleen Fitzpatrick	Member of Executive Committee			
Mirza Dautbegovic	Member of Executive Committee			
Seana Carson	Member of Executive Committee			
Tom Vadaketh	Member of Executive			

Committee

Board of directors			
John Paulson	Chairman of Supervisory Board		
Amy Wechsler	Member of Supervisory Board		
Richard Mulligan	Member of Supervisory Board		
Brett Icahn	Member of Supervisory Board		
Robert Power	Member of Supervisory Board		
Russel Robertson	Member of Supervisory Board		
Sarah Kavanagh	Member of Supervisory Board		
Steven Miller	Member of Supervisory Board		
Thomas Ross	Member of Supervisory Board		

